In today's financial climate, the survival of smaller companies is often dependent on their ability to do deals successfully with larger pharmaceutical companies. The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector, the latest report from PharmaVentures, provides expert guidance on critical aspects of deal-making, including valuations and royalty rate calculations.
Oxford, UK (PRWEB) November 5, 2008 -- In the current financial climate, the availability of venture capital will simply dry up, particularly for start-up biotech companies and those desperate for additional funding. This leaves many vulnerable companies with a critical need for cash, and their key to survival in the short-term will be deal-making with larger pharmaceutical and biotech companies. The market is now reacting to this depleted cash availability and so the terms of licensing deals are turning back in favour of those cash-rich pharmaceutical companies.
"For biotechs, protecting cash flow is key to survival, which means that licensing terms have become more crucial than ever before", claims Fintan Walton, CEO of PharmaVentures, a leading transactions firm. In fact, managing both financial as well as clinical risk will be vitally important according to the recently published report from PharmaVentures, The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector. "The adoption of the correct valuation models can enable companies to derive better value from their deal-making in these financially challenging times. The Report sets out to provide essential assessment through the most powerful methodologies available, selected case studies and PharmaVentures consultants' experience in deal making advisory services."
Nigel Borshell, Editor of the Report, says, "In these important times, the Report explodes some of the myths of valuations and royalty rates calculations, highlights what you should factor in to your own calculations and explains how best to generate useful royalty rate outcomes. It does this by providing key case histories, deal analysis, and opinion leader comment all relating to the quest for better more useable valuation data." A significant part of the content has been formulated by leveraging PharmaVentures' 16 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal-making.
Topics covered in the Report include:
According to Fintan Walton: "This report complements PharmaVentures' insight and expertise to the industry on these issues particularly through our advisory services and our pan media offerings, PharmaDeals and PharmaTelevision."
Notes to Editors:
PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of publishing products that include databases, analysis tools, and reports as well as PharmaTelevision, the industry's first dedicated online TV channel. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.
About the Report
The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector.
A Report by PharmaVentures, Edited by Nigel Borshell
Available in print and in electronic format
Table of Contents and Sample Pages
Related Video from PharmaTelevision
PharmaVentures: Valuation methods and trends in licensing deals
For further information about the Report and other PharmaDeals databases and publications, including ordering, please contact:
Oxford Science Park
OX4 4GA, UK
T: +44 (0) 1865 784 177
For information about PharmaTelevision, please contact:
Oxford Science Park
OX4 4GA, UK
T: +44 (0)1865 784 162
Read the full story at http://www.prweb.com/releases/2008/11/prweb1569194.htm
Copyright©2008 Vocus, Inc.
All rights reserved